Log in

NYSEAMERICAN:BPMX - Biopharmx Stock Price, Forecast & News

$0.39
-0.04 (-9.39 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.34
Now: $0.39
$0.41
50-Day Range
$0.31
MA: $0.35
$0.39
52-Week Range
$0.26
Now: $0.39
$4.46
Volume1.23 million shs
Average Volume542,438 shs
Market Capitalization$5.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BPMX
CUSIPN/A
CIKN/A
Phone+1-650-8895020

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$5.48 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.


Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

When did Biopharmx's stock split? How did Biopharmx's stock split work?

Shares of Biopharmx reverse split on the morning of Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) posted its quarterly earnings results on Monday, September, 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.11. View Biopharmx's Earnings History.

What price target have analysts set for BPMX?

2 analysts have issued twelve-month target prices for Biopharmx's stock. Their forecasts range from $1.00 to $1.00. On average, they expect Biopharmx's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 158.9% from the stock's current price. View Analyst Price Targets for Biopharmx.

What is the consensus analysts' recommendation for Biopharmx?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.

Has Biopharmx been receiving favorable news coverage?

Media stories about BPMX stock have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biopharmx earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Biopharmx.

Who are some of Biopharmx's key competitors?

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), CytRx (CYTR), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Protalix Biotherapeutics (PLX) and Jaguar Health (JAGX).

Who are Biopharmx's key executives?

Biopharmx's management team includes the folowing people:
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
  • Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs

Who are Biopharmx's major shareholders?

Biopharmx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Barclays PLC (1.23%) and Virtu Financial LLC (0.71%). Company insiders that own Biopharmx stock include Anja B Krammer, David S Tierney, Stephen Morlock and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Biopharmx.

Which major investors are selling Biopharmx stock?

BPMX stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold Biopharmx company stock in the last year include Anja B Krammer and Vivo Capital Viii, Llc. View Insider Buying and Selling for Biopharmx.

Which major investors are buying Biopharmx stock?

BPMX stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Biopharmx.

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $0.39.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $5.48 million. Biopharmx employs 17 workers across the globe.View Additional Information About Biopharmx.

What is Biopharmx's official website?

The official website for Biopharmx is http://www.biopharmx.com/.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel